AC   CVCL_1882
DR   BTO; BTO:0004847
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03151879
DR   BioSample; SAMN10988512
DR   cancercelllines; CVCL_1882
DR   Cell_Model_Passport; SIDM00093
DR   DepMap; ACH-000013
DR   DSMZ; ACC-507
DR   DSMZCellDive; ACC-507
DR   IARC_TP53; 27010
DR   LiGeA; CCLE_540
DR   PharmacoDB; ONCODG1_1200_2019
DR   Progenetix; CVCL_1882
DR   Wikidata; Q54936399
RX   PubMed=1381131;
RX   PubMed=14522906;
RX   PubMed=20143388;
RX   PubMed=23839242;
RX   PubMed=26589293;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Contaminated. Shown to be a OVCAR-3 derivative (PubMed=20143388). Originally thought to originate from a 49 year old female patient with a thyroid gland papillary carcinoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00338.
CC   Population: Caucasian.
CC   Doubling time: ~30 hours (DSMZ=ACC-507).
CC   HLA typing: A*02:01,29:02; B*07:02,58:01; C*07:02,07:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=14522906; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=4.26%; East Asian, South=0%; South Asian=0%; European, North=61.21%; European, South=34.52% (PubMed=30894373).
CC   Discontinued: DSMZ; ACC-507; true.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 13
ST   D19S433: 14,17
ST   D21S11: 29,31.2
ST   D2S1338: 17,21
ST   D3S1358: 17,18
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 8,15
ST   FGA: 21
ST   Penta D: 12,13
ST   Penta E: 7,13
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0465 ! OVCAR-3
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
RX   PubMed=1381131; DOI=10.1007/BF02899670;
RA   Grimm D., Hofstadter F., Bauer J., Spruss T., Steinbach P.,
RA   Bernhardt G., Menze R.;
RT   "Establishment and characterization of a human papillary thyroid
RT   carcinoma cell line with oxyphilic differentiation (ONCO-DG 1).";
RL   Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 62:97-104(1992).
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=23839242; DOI=10.1038/ncomms3126;
RA   Domcke S., Sinha R., Levine D.A., Sander C., Schultz N.;
RT   "Evaluating cell lines as tumour models by comparison of genomic
RT   profiles.";
RL   Nat. Commun. 4:2126.1-2126.10(2013).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).